BAP1 Testing in Instance Choroidal Nevi

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by Greater Houston Retina Research
Sponsor:
Information provided by (Responsible Party):
Amy C Schefler, MD, Greater Houston Retina Research
ClinicalTrials.gov Identifier:
NCT01925599
First received: August 15, 2013
Last updated: March 4, 2014
Last verified: March 2014
  Purpose

BAP1 serum germline, is a simple blood test in patients with nevi. This study aims to examine the rate of germline BAP1 mutations in young patients diagnosed with choroidal nevi to explore the role for this test as a screening tool in the future in this particular patient population.


Condition
Choroidal Nevi

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Identification of Germline BAP1 Mutation in Young Patients With Choroidal Nevi

Resource links provided by NLM:


Further study details as provided by Greater Houston Retina Research:

Primary Outcome Measures:
  • Examine the rate of germline BAP1 mutations in young patients, diagnosed with choroidal nevi [ Time Frame: 1 Year ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Whole Blood


Estimated Enrollment: 30
Study Start Date: July 2013
Estimated Study Completion Date: January 2017
Estimated Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Detailed Description:

A germline BAP1 mutation predisposes a person to developing uveal melanoma and other cancers. If a mutation is discovered, it changes the approach of managing the nevi. A "normal" case of an choroidal nevus involves less frequent follow up visits and in this time, the nevi could grow quickly. Closer follow up and more aggressive treatment could preserve the patient's vision and potentially prevent micrometastatic spread. This new screening technique will be able to extend the length and quality of life of patients with more frequent targeted cancer screens.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients age 18 and over and under age 65, diagnosed with choroidal nevi

Criteria

Inclusion Criteria:

any person with choroidal nevi

Exclusion Criteria:

any persons under the age of 18 and over the age of 65

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01925599

Contacts
Contact: Amy C Schefler, MD 713-524-3434 acsmd@houstonretina.com
Contact: Lesli Kao, BS 713-524-3434 leslie.kao@houstonretina.com

Locations
United States, Texas
Retina Consultants of Houston Recruiting
Houston, Texas, United States, 77030
Contact: Leslie Kao, BS    713-524-3434    leslie.kao@houstonretina.com   
Contact: Karri Schuetzle    713-524-3434    karri.schuetzle@houstonretina.com   
Principal Investigator: Amy C Schefler, MD         
Sponsors and Collaborators
Amy C Schefler, MD
Investigators
Principal Investigator: Amy C. Schefler, MD Retina Consultants of Houston
  More Information

Publications:
Responsible Party: Amy C Schefler, MD, Director of Ophthalmic Oncology, Greater Houston Retina Research
ClinicalTrials.gov Identifier: NCT01925599     History of Changes
Other Study ID Numbers: BAP101
Study First Received: August 15, 2013
Last Updated: March 4, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Greater Houston Retina Research:
Nevus
Choroidal Melanoma
BAP1 mutation

Additional relevant MeSH terms:
Nevus
Nevus, Pigmented
Nevi and Melanomas
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on July 24, 2014